GlobeNewswire: Karolinska Development AB (publ) Contains the last 10 of 671 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T06:18:59ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/22/2850792/0/en/Karolinska-Development-s-portfolio-company-Umecrine-Cognition-presents-positive-safety-data-from-the-first-part-of-its-Phase-1b-2-study-in-PBC.html?f=22&fvtc=4&fvtv=31102Karolinska Development’s portfolio company Umecrine Cognition presents positive safety data from the first part of its Phase 1b/2 study in PBC2024-03-22T08:30:41Z<![CDATA[STOCKHOLM, SWEDEN – March 22, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Umecrine Cognition has presented a positive safety data from the first part of its clinical Phase 1b/2 study of golexanolone in patients with Primary Biliary Cholangitis, PBC. The second part of the study, which will now be initiated, aims to evaluate the preliminary efficacy of the drug candidate and further study its safety and tolerability profile. Top-line results are expected in H1, 2025.]]>https://www.globenewswire.com/news-release/2024/03/22/2850792/0/sv/Karolinska-Developments-portf%C3%B6ljbolag-Umecrine-Cognition-presenterar-positiva-s%C3%A4kerhetsdata-fr%C3%A5n-f%C3%B6rsta-delen-av-bolagets-fas-1b-2-studie-i-PBC.html?f=22&fvtc=4&fvtv=31102Karolinska Developments portföljbolag Umecrine Cognition presenterar positiva säkerhetsdata från första delen av bolagets fas 1b/2-studie i PBC2024-03-22T08:30:41Z<![CDATA[STOCKHOLM, SVERIGE 22 mars 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar att portföljbolaget Umecrine Cognition har presenterat positiva säkerhetsdata från den första delen i bolagets kliniska fas 1b/2-studie av golexanolon i patienter med primär biliär kolangit, PBC. Nu inleds den andra delen av studien, vilken syftar till att utvärdera preliminär effekt av läkemedelskandidaten samt fortsatt utvärdering av säkerhets- och tolerabilitetsprofilen. Top line-resultat väntas under första halvåret 2025.]]>https://www.globenewswire.com/news-release/2024/03/22/2850755/0/en/Karolinska-Development-Annual-Report-2023-published.html?f=22&fvtc=4&fvtv=31102Karolinska Development Annual Report 2023 published2024-03-22T07:00:00Z<![CDATA[STOCKHOLM, SWEDEN – March 22, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces publication of its Annual Report 2023.]]>https://www.globenewswire.com/news-release/2024/03/22/2850755/0/sv/Karolinska-Developments-%C3%A5rsredovisning-f%C3%B6r-2023-har-publicerats.html?f=22&fvtc=4&fvtv=31102Karolinska Developments årsredovisning för 2023 har publicerats2024-03-22T07:00:00Z<![CDATA[STOCKHOLM, SVERIGE 22 mars 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att årsredovisningen för 2023 har offentliggjorts.]]>https://www.globenewswire.com/news-release/2024/03/14/2846193/0/en/Karolinska-Development-s-portfolio-company-Aprea-Therapeutics-receives-FDA-IND-approval-and-secures-funding-of-USD-34-million.html?f=22&fvtc=4&fvtv=31102Karolinska Development’s portfolio company Aprea Therapeutics receives FDA IND approval and secures funding of USD 34 million2024-03-14T11:48:31Z<![CDATA[STOCKHOLM, SWEDEN, March 14, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company Aprea Therapeutics has received FDA approval of the company’s IND application for the drug candidate APR-1051. Aprea has also secured funding up to USD 34 million through a financing round led by Sphera Healthcare. With the approval and financing in place, the company will be able to start the first clinical study with APR-1051.]]>https://www.globenewswire.com/news-release/2024/03/14/2846193/0/sv/Karolinska-Developments-portf%C3%B6ljbolag-Aprea-Therapeutics-f%C3%A5r-IND-godk%C3%A4nnande-fr%C3%A5n-FDA-och-s%C3%A4krar-finansiering-om-USD-34-miljoner.html?f=22&fvtc=4&fvtv=31102Karolinska Developments portföljbolag Aprea Therapeutics får IND-godkännande från FDA och säkrar finansiering om USD 34 miljoner2024-03-14T11:48:31Z<![CDATA[STOCKHOLM, SVERIGE 14 mars 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att portföljbolaget Aprea Therapeutics har fått IND-godkännande för läkemedelskandidaten APR-1051 från den amerikanska läkemedelsmyndigheten FDA. Aprea har även säkrat upp till USD 34 miljoner genom en finansieringsrunda som letts av Sphera Healthcare. Med godkännandet och finansieringen på plats har bolaget möjlighet att initera den första kliniska studien med APR-1051.]]>https://www.globenewswire.com/news-release/2024/03/14/2846120/0/en/Karolinska-Development-s-portfolio-company-Biosergen-publishes-prospectus-due-to-rights-issue-of-units.html?f=22&fvtc=4&fvtv=31102Karolinska Development’s portfolio company Biosergen publishes prospectus due to rights issue of units2024-03-14T10:24:14Z<![CDATA[STOCKHOLM, Sweden, March 14 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company Biosergen has published a prospectus for the issue of units that was approved during a extraordinary general meeting on March 1, 2024.]]>https://www.globenewswire.com/news-release/2024/03/14/2846120/0/sv/Karolinska-Developments-portf%C3%B6ljbolag-Biosergen-publicerar-prospekt-i-samband-med-emission-av-units.html?f=22&fvtc=4&fvtv=31102Karolinska Developments portföljbolag Biosergen publicerar prospekt i samband med emission av units2024-03-14T10:24:14Z<![CDATA[STOCKHOLM, SVERIGE 14 mars 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar att portföljbolaget Biosergen publicerat ett prospekt med anledning av en företrädesemission av units som sker med stöd av godkännande på en extra bolagsstämma den 1 mars, 2024.]]>https://www.globenewswire.com/news-release/2024/03/06/2841087/0/en/Karolinska-Development-s-portfolio-company-Umecrine-Cognition-presents-preclinical-Parkinson-s-data-on-golexanolone-at-AD-PD.html?f=22&fvtc=4&fvtv=31102Karolinska Development’s portfolio company Umecrine Cognition presents preclinical Parkinson’s data on golexanolone at AD/PD2024-03-06T08:00:00Z<![CDATA[STOCKHOLM, SWEDEN – March 6, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Umecrine Cognition will present recent nonclinical data elucidating golexanolone’s mode-of-action in Parkinson’s disease at the 18th International Conference on Alzheimer’s and Parkinson’s Diseases 2024 in Lisbon, Portugal, during March 5-9.]]>https://www.globenewswire.com/news-release/2024/03/06/2841087/0/sv/Karolinska-Developments-portf%C3%B6ljbolag-Umecrine-Cognition-presenterar-prekliniska-Parkinsondata-f%C3%B6r-golexanolon-p%C3%A5-AD-PD.html?f=22&fvtc=4&fvtv=31102Karolinska Developments portföljbolag Umecrine Cognition presenterar prekliniska Parkinsondata för golexanolon på AD/PD2024-03-06T08:00:00Z<![CDATA[STOCKHOLM, SVERIGE 6 mars 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar att portföljbolaget Umecrine Cognition presenterar nyligen genererade prekliniska resultat som belyser golexanolons verkningsmekanism i Parkinsons sjukdom under den årliga konferensen 18th International Conference on Alzheimer´s and Parkinson´s Diseases 2024 i Lissabon, Portugal, mellan den 5-9 mars.]]>